This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Treatment of Paget's Disease and Osteogenesis Imperfecta

Edythe B. Goldfield, MD; Barry M. Braiker, MD; J. Joseph Prendergast, MD; Felix O. Kolb, MD

JAMA. 1972;221(10):1127-1129.

Abstract
Synthetic salmon calcitonin was given daily for 90 days as a subcutaneous dose of 50 Medical Research Council units to three patients with active Paget's disease and one patient with osteogenesis imperfecta. Symptomatic improvement occurred in two of the patients with Paget's disease and in the patient with osteogenesis imperfecta. During the three months of treatment, serum alkaline phosphatase, urinary hydroxyproline, and urinary calcium decreased significantly in the patients with Paget's disease, and, in the patient with osteogenesis imperfecta, urinary hydroxyproline decreased, suggesting that this new form of calcitonin is also effective in reducing bone resorption in these diseases. No adverse reactions were observed in our initial studies.

Author Affiliations
From the Metabolic Research Unit and Department of Orthopedic Surgery, University of California, San Francisco.

Footnotes
Reprint requests to Metabolic Research Unit, 1143-HSW, University of California, San Francisco 94122 (Dr. Kolb).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Treatment of Paget Disease of Bone (Osteitis Deformans) Results of a One-Year Study With Sodium Etidronate
Khairi et al.
JAMA 1974;230:562-567.
ABSTRACT